Moderna, Inc. — Director's Dealing 2021

Nov 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-11-23

Reporting Person: Hoge Stephen (President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-23	Common Stock	M	5000	$10.90	Acquired	1614597	Direct
2021-11-23	Common Stock	M	10000	$0.99	Acquired	1624597	Direct
2021-11-23	Common Stock	S	196	$270.19	Disposed	1624401	Direct
2021-11-23	Common Stock	S	1600	$271.84	Disposed	1622801	Direct
2021-11-23	Common Stock	S	1368	$273.10	Disposed	1621433	Direct
2021-11-23	Common Stock	S	1863	$274.19	Disposed	1619570	Direct
2021-11-23	Common Stock	S	1977	$275.22	Disposed	1617593	Direct
2021-11-23	Common Stock	S	2096	$276.32	Disposed	1615497	Direct
2021-11-23	Common Stock	S	5300	$277.25	Disposed	1610197	Direct
2021-11-23	Common Stock	S	200	$278.48	Disposed	1609997	Direct
2021-11-23	Common Stock	S	400	$280.14	Disposed	1609597	Direct
2021-01-24	Common Stock	M	5000	$10.90	Acquired	1614597	Direct
2021-01-24	Common Stock	S	5000	$273.01	Disposed	1609597	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-23	Stock Option (Right to Buy)	$10.90	M	5000	Disposed	2026-02-23	Common Stock (5000)	Direct
2021-11-23	Stock Option (Right to Buy)	$0.99	M	10000	Disposed	2023-08-19	Common Stock (10000)	Direct
2021-11-24	Stock Option (Right to Buy)	$10.90	M	5000	Disposed	2026-02-23	Common Stock (5000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4116	Indirect
Common Stock	151933	Indirect

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $269.86 to $270.50. Full information regarding the number of shares sold at each separate ice can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $271.52 to $272.50. Full information regarding the number of shares sold at each separate ice can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $272.62 to $273.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $273.72 to $274.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $274.80 to $275.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $275.85 to $276.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $277.08 to $277.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $278.15 to $278.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $279.80 to $280.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F11: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F12: This option is fully vested and exercisable.